GemVax's Highly Promising Phase II Alzheimer's Disease Clinical Trial Results Targeting Telomerase Published in Alzheimer's Research & Therapy' Journal
March 30, 2021 at 06:48 am EDT
Share
GemVax & KAEL Co. Ltd. has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal 'Alzheimer's Research & Therapy'. The paper is titled 'Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial', and contains an analysis of the overall data from the Phase II clinical trial for Alzheimer's disease conducted in Korea. Publication in such a peer-reviewed journal is regarded as further vindication of GemVax's decision to advance GV1001 into a Phase III trial in Korea later this year. The phase II clinical trial was conducted at twelve domestic institutions to evaluate the safety and efficacy of GV1001, and confirmed statistically significant improvements in both the primary and secondary endpoints, the Severe Impairment Battery (SIB) (7.1 points) and the neuropsychiatric inventory (NPI) score, respectively. In particular, GV1001 was well tolerated without any clinically significant side effects or adverse drug events.
GemVax & KAEL Co.,Ltd is a Korea-based company mainly engaged in the manufacture of pollution control equipment used in semiconductor manufacturing processes. The Company and its subsidiaries are engaged in the three categories of businesses: pollution control business, which manufactures chemical air (CA) filters, gas scrubbers, resins, coating resins and other environmental equipments and systems; anticancer and anti-inflammation business, which engages in development of cancer vaccines for infectious diseases, such as acquired immune deficiency syndrome (AIDS) and anti-inflammations, and IT business which mainly produces liquid crystal display (LCD) modules. The Company distributes its products within domestic market and to overseas markets.
GemVax's Highly Promising Phase II Alzheimer's Disease Clinical Trial Results Targeting Telomerase Published in Alzheimer's Research & Therapy' Journal